Incidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study
Surgical Endoscopy · 2024
DOI: 10.1007/s00464-024-11327-3 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Surgical Endoscopy, 2024. Verfasst von Beth A VanderWielen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 1St Street SW, Rochester, MN, 55905, USA. vanderwielen.beth@mayo.edu. Hauptthemen laut MEDLINE: Neurokinin-1 Receptor Antagonists, Postoperative Nausea and Vomiting. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Mayo Clinic.
Abstract (Originalsprache)
BACKGROUND: Both the transoral gastric reduction (TORe) and endoscopic sleeve gastroplasty (ESG) procedures are novel endoscopic bariatric and metabolic therapies (EBMT). Our practice has an aggressive approach to prophylaxis of postoperative nausea and vomiting (PONV) for EBMT cases, but there is divergence of practice regarding use of prophylactic neurokinin-1 receptor (NK-1) antagonists (aprepitant, fosaprepitant). Herein, we determined the incidence of PONV and its potential association with NK-1 antagonist administration following EBMT. METHODS: We identified and reviewed medical records of patients who underwent EBMT between 2018 and 2023. Patients were divided into those administered or not administered an NK-1 antagonist. We analyzed rates of PONV, which was defined as rescue antiemetics during anesthesia recovery. A propensity score was calculated, and outcomes were assessed using generalized estimating equations with inverse probability of treatment weighting (IPTW). RESULTS: We identified 404 patients undergoing EBMT (256 [63%] TORe, 148 [37%] ESG), and of these 253 patients developed PONV, (62.6% [95% CI: 57.9% to 67.3%]). NK-1 antagonists were administered to 119 (29.5%) patients. PONV was experienced by 42 (35%) and 211 (74%) of patients who were or were not administered an NK-1 antagonist, respectively (IPTW OR = 0.18, [95%CI: 0.10 to 0.31], P < 0.001). CONCLUSIONS: EBMT has a high incidence of PONV during anesthesia recovery. Administration of a NK-1 antagonist as part of a multiagent PONV prophylaxis regimen dramatically reduces risk for this common adverse event.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 1St Street SW, Rochester, MN, 55905, USA. vanderwielen.beth@mayo.edu.
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
- Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
- Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 1St Street SW, Rochester, MN, 55905, USA.
ORCID-Profile: Beth A VanderWielen
Förderung
- Mayo Clinic
Zitieren
APA
VanderWielen, B. A., Storm, A. C., Schroeder, D. R., Sprung, J., & Weingarten, T. N. (2024). Incidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study. Surgical Endoscopy. https://doi.org/10.1007/s00464-024-11327-3
Vancouver
VanderWielen BA, Storm AC, Schroeder DR, Sprung J, Weingarten TN. Incidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study. Surgical Endoscopy. 2024. doi:10.1007/s00464-024-11327-3
BibTeX
@article{VanderWielen2024,
author = {VanderWielen, Beth A and Storm, Andrew C and Schroeder, Darrel R and Sprung, Juraj and Weingarten, Toby N},
title = {Incidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study},
journal = {Surgical Endoscopy},
year = {2024},
doi = {10.1007/s00464-024-11327-3}
}
EUVIMED